Bridged Urea Sirtuin Modulators for Therapeutic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to modulate sirtuin proteins for treating a wide range of diseases related to aging, stress, diabetes, obesity, neurodegenerative disorders, and cardiovascular diseases, with existing treatments often having limitations in specificity and efficacy.
Innovation Solution
Development of novel sirtuin-modulating compounds that increase or decrease the activity of sirtuin proteins, administered alone or in combination with other therapeutic agents, to target specific diseases by modulating mitochondrial activity and deacetylase function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used to modulate sirtuin proteins, then some therapeutic effect is achieved, but specificity and efficacy are limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of sirtuin modulating compounds through various substitutions at specific positions (R1, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, X3, X4, Y1, Y2, Y3, Y4, Z1, Z2, Z3, Z4) to optimize both therapeutic efficacy and selectivity for sirtuin proteins, thereby improving reliability while maintaining manageable complexity
Solution Approach 2:
The patent segments the sirtuin modulating compound into distinct structural domains with specific substitution patterns, allowing for targeted optimization of different functional regions to enhance therapeutic effect while managing overall molecular complexity
2Reliability
If novel sirtuin-modulating compounds are developed to increase or decrease sirtuin protein activity, then therapeutic benefits for various diseases are achieved, but the complexity of compound structure and synthesis increases
Solution Approach 1:
The patent systematically varies chemical parameters including substituent types, positions, and configurations to create a library of sirtuin modulating compounds with optimized therapeutic benefits while establishing structure-activity relationships that guide further development
Solution Approach 2:
The patent develops a universal scaffold structure that can modulate different sirtuin proteins (SIRT1-SIRT7) through systematic substitution, allowing a single core structure to serve multiple therapeutic purposes across different diseases and targets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively increase or decrease sirtuin protein activity, offering therapeutic benefits for various diseases, including extending lifespan, treating diabetes, obesity, neurodegenerative disorders, and cardiovascular diseases, by enhancing mitochondrial function and deacetylase activity.
Implementation Method 1
Sir2 is a class III deacetylase which uses NAD as a cosubstrate. Deacetylation of acetyl-lysine by Sir2 is tightly coupled to NAD hydrolysis, producing nicotinamide and a novel acetyl-ADP ribose compound.
Implementation Method 2
Deacetylation of acetyl-lysine by Sir2 is tightly coupled to NAD hydrolysis, producing nicotinamide and a novel acetyl-ADP ribose compound.
Implementation Method 3
SIRT3 is a homolog of SIRT1 that is conserved in prokaryotes and eukaryotes. The SIRT3 protein is targeted to the mitochondrial cristae by a unique domain located at the N-terminus.
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
Provided herein are novel substituted bridged urea and related analogs and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.